Background: Neoadjuvant chemoradiation is currently standard of care in stage II-III rectal cancer, resulting in tumor downstaging for patients with treatment-responsive disease. However, the prognosis of the downstaged patient remains controversial. This work critically analyzes the relative contribution of pre-and post-therapy staging to the anticipated survival of downstaged patients. Methods: The National Cancer Database (NCDB) was queried for patients with rectal cancer treated with transabdominal resection between 2004 and 2014. Stage II-III patients downstaged with neoadjuvant radiation were compared with stage I patients treated with definitive resection alone. Patients with positive surgical margins were excluded. Overall survival was evaluated using both Kaplan-Meier analyses and Cox proportional hazards models. All statistical tests were two-sided. Results: A total of 44 320 patients were eligible for analysis. Survival was equivalent for patients presenting with cT1N0 disease undergoing resection (mean survival ¼ 113.0 months, 95% confidence interval [CI] ¼ 110.8 to 115.3 months) compared with those downstaged to pT1N0 from both cT3N0 (mean survival ¼ 114.9 months, 95% CI ¼ 110.4 to 119.3 months, P ¼ .12) and cT3N1 disease (mean survival ¼ 115.4 months, 95% CI ¼ 110.1 to 120.7 months, P ¼ .22). Survival statistically significantly improved in patients downstaged to pT2N0 from cT3N0 disease (mean survival ¼ 109.0 months, 95% CI ¼ 106.7 to 111.2 months, P < .001) and cT3N1 (mean survival ¼ 112.8 months, 95% CI ¼ 110.0 to 115.7 months, P < .001), compared with cT2N0 patients undergoing resection alone (mean survival ¼ 100.0 months, 95% CI ¼ 97.5 to 102.5 months). Multiple survival analysis confirmed that final pathologic stage dictated long-term outcomes in patients undergoing neoadjuvant radiation (hazard ratio [HR] of pT2 ¼ 1.24, 95% CI ¼ 1.10 to 1.41; HR of pT3 ¼ 1.81, 95% CI ¼ 1.61 to 2.05; HR of pT4 ¼ 2.72, 95% CI ¼ 2.28 to 3.25, all P .001 vs pT1; HR of pN1 ¼ 1.50, 95% CI ¼ 1.41 to 1.59; HR of pN2 ¼ 2.17, 95% CI ¼ 2.00 to 2.35, both P < .001 vs pN0); while clinical stage at presentation had little to no predictive value (HR of cT2 ¼ 0.81, 95% CI ¼ 0.69 to 0.95, P ¼ .008; HR of cT3 ¼ 0.83, 95% CI ¼ 0.72 to 0.96, P ¼ .009; HR of cT4 ¼ 1.02, 95% CI ¼ 0.85 to 1.21, P ¼ .87 vs cT1; HR of cN1 ¼ 0.96, 95% CI ¼ 0.91 to 1.02, P ¼ .19; HR of cN2 ¼ 0.96, 95% CI ¼ 0.86 to 1.08, P ¼ .48 vs cN0). Conclusions: Survival in patients with rectal cancer undergoing neoadjuvant radiation is driven by post-therapy pathologic stage, regardless of pretherapy clinical stage. These data will further inform prognostic discussions with patients.
Colorectal cancer is the third most common malignancy in the United States, with an anticipated 135 000 cases diagnosed in 2017 (1) . Incidence and mortality rates continue to decline in both colon and rectal cancer, largely due to improvements in both early screening and multidisciplinary treatment modalities (2) . Prior to the use of multimodality therapy, local recurrence was especially common in rectal cancer, resulting in poor longterm outcomes (3) . The introduction of neoadjuvant radiotherapy has decreased local recurrence rates by approximately 50% to 60% (4), with chemotherapy further improving both progression-free and overall survival (5) . The current standard of care for most patients with stage II and III rectal cancer is neoadjuvant chemotherapy with radiation, followed by complete surgical resection (6, 7) .
As neoadjuvant chemoradiation regimens continue to improve, the patient population clinically benefitting from tumor downstaging prior to surgery is growing. It has been demonstrated that downstaged tumors are associated with improved survival compared with therapy-resistant tumors (8) (9) (10) (11) (12) (13) . However, estimates of overall survival in downstaged patients continue to vary, as recent studies have provided conflicting evidence (8, 14, 15) . Specifically, it remains unclear whether longterm outcomes are tied more closely to baseline or postoperative disease stage.
To address this gap in prognostic knowledge, we aimed to examine the prognostic utility of pathologic stage as compared with clinical stage in patients downstaged with neoadjuvant therapy. This work queries a large national database for patients with rectal cancer who underwent transabdominal resection over a 10-year time period.
Methods

Patients
A retrospective review of the National Cancer Database (NCDB) was performed. The NCDB is a hospital-based national registry of cancer patients and a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data files used are compliant with the United States Health Insurance Portability and Accountability Act (HIPAA) and de-identified. The participant user file analyzed in this study included all patients diagnosed with rectal cancer from 2004 through 2014.
Patient characteristics examined included age at diagnosis, sex, tumor grade, margin status, receipt of chemotherapy, receipt of neoadjuvant radiation, and clinical (c) and pathologic (p) TNM stage. Patients with incomplete data were excluded, with the exception of tumor grade, as this information was unavailable in over 2500 cases. High tumor grade was defined as poor differentiation. Margin status postresection was defined as positive or negative. Clinical and pathologic TNM staging was performed according to American Joint Committee on Cancer (AJCC) guidelines, with 54% and 46% of patients classified according to the 6th edition and 7th editions, respectively. Importantly, T stage according to depth of invasion and N stage according to nodal metastasis were largely unchanged between the AJCC editions for rectal cancer (16) , and the data were therefore combined for the purposes of this manuscript.
In total, 243 466 patients with rectal cancer diagnosed between 2004 and 2014 were eligible for analysis from the NCDB. Inclusion criteria for this analysis consisted of histologically proven rectal adenocarcinoma in patients undergoing curative-attempt surgical resection. Patients with metastatic disease were excluded. Patients who underwent local excision and those with positive surgical margins were excluded because these patients have higher rates of local recurrence. Finally, as adjuvant radiation was uncommon (10.9%) and the reasons for adjuvant radiation were unknown, these patients were also excluded. In addition, while the vast majority of patients undergoing neoadjuvant radiation received chemotherapy (97.5%), the timing of chemotherapy was unknown. Chemotherapy was therefore excluded as a separate variable in this analysis. A detailed inclusion diagram is shown in Figure 1 .
Statistical Analysis
All statistical analyses were performed using IBM SPSS Statistics version 24. A P value of less than .05 was considered statistically significant. Categorical variables were compared using the exact chi-square test, and continuous variables were compared using the two independent samples t test. Survival curves were estimated using Kaplan-Meier methodology and compared between two groups using the log-rank test. Univariate analysis of overall survival was performed using a Cox proportional hazards regression model. The proportional hazards assumption was validated graphically using model checking (log minus log) plots for each variable. All variables that were statistically significant on univariate analysis (P < .05) were included in a multivariable Cox proportional hazards regression model. To adjust for selection bias, inverse probability weighting was performed based on the predicted probability of inclusion in the main study population for an expanded population including subjects with local excision, positive margins, metastatic disease, and adjuvant radiotherapy. Weights were applied to logistic regression analyses to predict three-year and five-year mortality using covariates included in the original analysis. All statistical tests were two-sided unless otherwise indicated.
Results
Patient Population
A total of 44 320 patients were included in the final analysis: 13 736 patients undergoing surgical resection up front and 30 584 patients who received neoadjuvant radiation prior to surgical resection. Baseline characteristics of each group are detailed in Table 1 . Patients who underwent neoadjuvant radiation tended to be younger and female. Neoadjuvant radiation was used most commonly in clinical stage II-III disease, while those patients who did not undergo radiation were largely clinical stage I, consistent with National Comprehensive Cancer Network (NCCN) guidelines (7) . Importantly, of the 13 736 patients who did not undergo radiation, 3872 were pT1N0 and 4287 were pT2N0, accounting for only 59.4% of this cohort. Thus, 40.6% of the patients who underwent surgery without radiation had pathologic stage II-III disease, discordant with NCCN guidelines.
Clinical and Pathologic Staging Concordance
We first sought to evaluate the accuracy of clinical staging in this group of patients. As such, the concordance between clinical and pathologic staging was assessed in patients undergoing surgery up front. In the absence of neoadjuvant radiation, 
Outcomes
While it has been previously demonstrated that patients responding to neoadjuvant radiation fare better than nonresponders, it remains unclear whether patients survive in a manner that most closely associates with either their pre-or postneoadjuvant therapy stage. To assess this, we compared outcomes of patients resected without neoadjuvant therapy (ie, pStageX) with those downstaged with neoadjuvant radiation to a similar stage (ie, ypStageX). All patients with final pT1N0 disease demonstrated similar overall survival, regardless of their clinical stage prior to therapy (mean survival of cT1N0 ¼ 113.0 months, 95% confidence interval [CI] ¼ 110.8 to 115.3 months; mean survival of cT2N0 ¼ 110.9 months, 95% CI ¼ 104.1 to 117.6 months; mean survival of cT3N0 ¼ 114.9 months, 95% CI ¼ 110.4 to 119.3 months; P ¼ .18 cT1N0 vs cT2N0, P ¼ .12 cT1N0 vs cT3N0) ( Figure 2A , Table 2 ). This also held true for patients with clinical N1 disease who downstaged to pT1N0 (mean survival of cT2N1 ¼ 110.0 months, 95% CI ¼ 99.7 to 120.4 months; mean survival of cT3N1 ¼ 115.4 months, 95% CI ¼ 110.1 to 120.7 months; P ¼ .44 cT1N0 vs cT2N1, P ¼ .22 cT1N0 vs cT3N1) ( Figure 2B , Table 2 Figure 2D , Table 2 ). The impact of final pathologic stage on long-term outcomes was then assessed within clinically stage-matched patients undergoing neoadjuvant radiation. In clinical T3N0 disease, Supplementary Figure 2A Figure 2C, available online) . In both instances, the degree of downstaging predicted prolonged survival. Taken together, these data demonstrate that the prognosis for stage II-III patients with rectal cancer downstaged by neoadjuvant radiation is equivalent or superior to patients undergoing up-front surgery for stage I disease.
To further test if final pathologic stage is a better predictor of long-term outcomes than clinical stage in patients undergoing neoadjuvant radiation, a Cox proportional hazards model was employed. disease proceeding directly to definitive transabdominal resection (black, mean survival ¼ 100.0 months, 95% CI ¼ 97.5 to 102.5 months) compared with patients downstaged with neoadjuvant radiation from cT3N1 (gray, mean survival ¼ 112.8 months, 95% CI ¼ 110.0 to 115.7 months, P < .001 vs cT2N0) or cT4N1 (dashed, mean survival ¼ 97.7 months, 95% CI ¼ 85.4 to 110.0 months, P ¼ .79 vs cT2N0) to pathologic T2N0 disease. P values were calculated using the two-sided log rank test. Tables 1 and 2 , available online). Therefore, in surgical patients undergoing neoadjuvant radiation for rectal cancer, the final pathologic stage should be the primary determinant of long-term survival, regardless of pretherapy clinical stage. In order to address the application of strict exclusion criteria applied to such a large data set, inverse probability weighting (IPW) was applied. Logistic regression was performed using IPW based on the probability of inclusion in the main study to an expanded cohort of patients with local excision, positive margins, metastatic disease, and adjuvant radiotherapy. Factors associated with increased odds of death within three years (Supplementary Table 3 , available online) and five years (Supplementary Table 4 , available online) included advanced age, male sex, poor tumor differentiation, and mucinous or signet ring histology. Pathologic staging again demonstrated greater discrimination than clinical staging.
Discussion
The prognosis associated with downstaging in rectal cancer after neoadjuvant therapy remains difficult to quantify. Using a large database such as the NCDB and evaluating more than 40 000 patients with rectal cancer over a 10-year time period, our study provides objective data to help answer this important clinical question. We show that patients downstaged to stage I disease with neoadjuvant radiotherapy demonstrate similar, if not better, survival than stage I patients proceeding directly to resection. In fact, all patient groups with evidence of downstaging demonstrate similar, if not better, survival than similarly pathologic staged patients having gone straight to surgery. Thus, pretherapy stage appears to have little influence on survival in patients undergoing neoadjuvant therapy. Rather, posttherapy pathologic stage (and the degree of downstaging) best predicts long-term outcomes. This represents the largest study to date analyzing survival in downstaged rectal cancer patients, demonstrating that final pathologic stage best dictates overall survival, regardless of pretherapy clinical stage.
Our findings are in agreement with a smaller study conducted by Quah et al., in which the authors queried a singleinstitution database for stage II-III rectal cancers treated with neoadjuvant radiation and incorporated multiple calculations to assess histopathologic response to therapy (8) . While our methodologies differ, the result appears to be similar: final pathologic stage after radiation is highly predictive of long-term outcomes. However, there are discordant data in the literature (17, 18) . In line with these findings, we demonstrate a progressive survival benefit with increasing downstaging for pathologic stage I-III patients. Thus, the survival advantage seen is likely a reflection of inherent tumor biology and overall treatment sensitivity. Accordingly, the Neoadjuvant Rectal (NAR) Score was recently developed to quantify tumor regression. Although the NAR has yet to be formally validated as a substitute for long-term survival, it now serves as a surrogate end point for National Cancer Institute-approved phase II clinical trials (19) . To our knowledge, this is the largest study of its kind to evaluate downstaged rectal cancer patients. Pathologic T1N0 patients, regardless of baseline presentation or downstaged from stage III disease, display equivalent survival patterns. In fact, pT2N0 patients having proceeded directly to surgery exhibited statistically significantly reduced survival compared with cT3N0 or cT3N1 patients who were downstaged to pT2N0 with neoadjuvant therapy. These data suggest a potential role for neoadjuvant therapy in T2N0 disease. It was particularly noteworthy that pretherapy clinical stage appeared to be inconsistent in predicting outcomes, representing a potential paradigm shift in the management of these patients. The issue is further compounded by our study showing that 40.6% of patients not receiving neoadjuvant radiation had pathologic stage II-III disease, discordant with current National Comprehensive Cancer Network (NCCN) guidelines (7) . These conclusions favoring neoadjuvant therapy may be limited by confounding disparities between patients undergoing neoadjuvant radiation and those proceeding directly to surgery. However, multivariable analysis adjusting for age, sex, and pathologic tumor grade nonetheless continued to demonstrate that final pathologic stage dictated outcome in patients undergoing neoadjuvant radiation, while advanced clinical stage demonstrated no statistically significant association with survival.
Men demonstrated poor long-term outcomes compared with women, a finding commonly reported in rectal cancer cohorts (20) (21) (22) (23) . The etiology of this gender disparity remains unclear. Previous investigators have claimed this to be purely an agerelated effect (24) . However, our data demonstrate reduced survival in men when adjusted for both age and stage, suggesting alternative reasons behind this difference. Anatomical differences may contribute, as women typically have wider pelvic dimensions, which may be further elucidated with the development of imaging-based volumetric calculators.
This study has several limitations. First, the large, hospitalmaintained, retrospective database affords little control over local practices. As such, chemotherapies, radiation regimens, and surgical procedures are grouped broadly, and we are unable to evaluate and adjust for specific techniques, doses, or regimens. It is worth mentioning that 29 784 (97.5%) patients undergoing neoadjuvant radiation also received chemotherapy in some form. Given this concordance and a lack of data regarding timing of systemic therapy, chemotherapy was excluded as a separate variable in this analysis. The relative impact of chemotherapy on a durable downstaging effect on survival represents an area of active investigation in our group.
In addition, the absence of local recurrence and disease-free survival data in the NCDB limits our ability to understand the mode of failure in patients with poor survival. The database also fails to incorporate molecular profiling of tumors that might offer insights into inherent radiation or chemotherapy resistance or other prognostic markers that drive some of these observed differences. Further, our definition of downstaging assumes a high degree of accuracy in clinical staging. At this time, the NCDB does not distinguish patients staged with endoscopic ultrasound vs magnetic resonance imaging (MRI). This information could prove valuable in the future as superiority between these methods remains contentious. The timing of surgery after neoadjuvant regimens remains variable among institutions and represents a future direction, as the optimal interval between radiation and surgery remains controversial (25) . Perhaps the most important limitation of our data set is the number of excluded patients due to missing data. In fact, the majority of patients were excluded from this analysis due to missing clinical staging. While the NCDB is actively working on resolving these issues, we have nonetheless captured the largest group of patients to be studied in this manner to date.
In summary, we demonstrate that the final pathologic stage is the most reliable marker of overall survival after neoadjuvant therapy in rectal cancer. Downstaged patients survive equivalent, if not better, than pathologic stage-matched patients who proceeded directly to resection. These data will be invaluable for advocating consistency in guideline adherence to the use of neoadjuvant therapy and providing improved discussions with downstaged patients regarding prognosis. Additionally, these data will help direct organ-sparing approaches to the subset of downstaged patients while focusing future research efforts on patients with therapy-resistant tumors.
